JACKSONVILLE, Florida, August 25, 2016 /PRNewswire/ --
TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology
company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of
cancer & metastatic disease, is pleased to announce the appointment of Michael J. Loiacono as
its Chief Financial Officer and Chief Accounting Officer. Michael will also act as Corporate Secretary. Michael has served
an advisory role to the Company as finance consultant to TapImmune since March 2016.
Michael served as CFO of Global Axcess Corporation, a publicly-traded company, from 2006-2013 where he was responsible for the
overall strategy of the company including capital raises, mergers & acquisitions, corporate finance, treasury, accounting and
investor relations. Upon the acquisition of Global Axcess by FCTI, Inc., he was responsible for the company's strategic
development including new products and services, entrance into new markets and maximizing gross and net revenues. In 2009,
he was named the "Jacksonville Florida Ultimate CFO of the year" by the Jacksonville Business Journal.
Prior to Global Axcess/FCTI Michael held various positions of increasing responsibility in finance management through several
private and publicly-traded organizations. He has a degree in Business Management from Rutgers
University, Business School, NJ.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome Michael to a key
position in the TapImmune management team. As an advisor to the Company, Michael has clearly demonstrated his financial skills
and ability to professionally lead our finance and accounting functions consistent with our projected up-list to the Nasdaq
National Markets."
"It's truly an exciting opportunity to join an industry-leader like TapImmune and be a part of the management team," said Mr.
Loiacono, "The Company has become a leader in the area of immuno-oncology as a result of innovative science, passionate employees
and talented researchers. I look forward to working with this fantastic team as we continue to forge ahead in this very
important industry and bring increased value to our shareholders."
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of
cancer, including metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple
naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to
restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's
technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the
Company's website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any
other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings
which are available through EDGAR at http://www.sec.gov . The Company assumes no
obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-7541
SOURCE TapImmune Inc.